TAS-102 not checked

Taiho

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 1 trial completes
Trials
1 active
13 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“TAS-102 will be administered orally twice daily at a dose calculated based on body surface area (BSA) within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.”In the company’s words, NCT04999761 on ClinicalTrials.gov
Tested for
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma, Esophageal Cancer, Head and Neck Cancer and 1 more
Main trialPhase 1
“This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.”In the company’s words, NCT04999761 on ClinicalTrials.gov
Other names
Lonsurf · Oral Solution

Other drugs for Advanced or Metastatic Solid Tumor

All 302 drugs for Advanced or Metastatic Solid Tumor

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials13

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Jun 2027 AB122 Platform Study
Phase 3Completed 31 Jan 2014 Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Phase 3Completed 30 Apr 2018 Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
Phase 2Terminated Jun 2014 A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
Phase 2Completed Aug 2017 A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
Phase 1Completed Oct 2013 Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
Phase 1Completed Aug 2014 Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors
Phase 1Completed Nov 2014 Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Phase 1Completed Aug 2015 Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI
Phase 1Completed Oct 2015 A Phase I Study of TAS-102 in Solid Tumors
Phase 1Completed Jun 2016 A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Phase 1Completed Sep 2017 A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
Phase 1Completed 19 Jun 2019 A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TAS-102

Following is part of Solo: you see every change to TAS-102 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in